{"id":949190,"date":"2026-04-06T16:08:40","date_gmt":"2026-04-06T20:08:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/"},"modified":"2026-04-06T16:08:40","modified_gmt":"2026-04-06T20:08:40","slug":"shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/","title":{"rendered":"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA"},"content":{"rendered":"
\n

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc.<\/strong> (“Atara Biotherapeutics, Inc.” or the “Company”) (NASDAQ: ATRA) of a class action securities lawsuit.<\/p>\n

\n CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Atara Biotherapeutics, Inc. investors who were adversely affected by alleged securities fraud between May 20, 2024 and January 9, 2026. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/atara-biotherapeutics-inc-lawsuit-submission-form?prid=185160&wire=3<\/a>\u00a0<\/p>\n

\n ATRA<\/strong> investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/strong>The filed complaint alleges that defendants made false statements and\/or concealed that: (i) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel\u2019s regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (iv) all the foregoing was likely to have a significant negative impact on Atara\u2019s business and financial condition; and (v) as a result, defendants\u2019 public statements were materially false and\/or misleading at all relevant times.<\/p>\n

\n WHAT’S NEXT? <\/strong>If you suffered a loss in Atara Biotherapeutics, Inc. during the relevant time frame, you have until May 22, 2026<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/strong><\/p>\n

\n WHY LEVI & KORSINSKY: <\/strong>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n CONTACT:<\/strong>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>\u00a0
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. (“Atara Biotherapeutics, Inc.” or the “Company”) (NASDAQ: ATRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Atara Biotherapeutics, Inc. investors who were adversely affected by alleged securities fraud between May 20, 2024 and January 9, 2026. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/atara-biotherapeutics-inc-lawsuit-submission-form?prid=185160&wire=3\u00a0 ATRA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) certain manufacturing issues, as well … <\/p>\n

Continue reading “Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949190","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nShareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. (“Atara Biotherapeutics, Inc.” or the “Company”) (NASDAQ: ATRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Atara Biotherapeutics, Inc. investors who were adversely affected by alleged securities fraud between May 20, 2024 and January 9, 2026. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/atara-biotherapeutics-inc-lawsuit-submission-form?prid=185160&wire=3\u00a0 ATRA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) certain manufacturing issues, as well … Continue reading "Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-06T20:08:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA\",\"datePublished\":\"2026-04-06T20:08:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/\"},\"wordCount\":420,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/\",\"name\":\"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=\",\"datePublished\":\"2026-04-06T20:08:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA - Market Newsdesk","og_description":"NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. (“Atara Biotherapeutics, Inc.” or the “Company”) (NASDAQ: ATRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Atara Biotherapeutics, Inc. investors who were adversely affected by alleged securities fraud between May 20, 2024 and January 9, 2026. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/atara-biotherapeutics-inc-lawsuit-submission-form?prid=185160&wire=3\u00a0 ATRA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) certain manufacturing issues, as well … Continue reading \"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-06T20:08:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA","datePublished":"2026-04-06T20:08:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/"},"wordCount":420,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/","name":"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=","datePublished":"2026-04-06T20:08:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA5OSM3NTE2NTc4IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-atara-biotherapeutics-inc-atra-should-contact-levi-korsinsky-about-pending-class-action-atra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action – ATRA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949190"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949190\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}